FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 323:1367-1374 November 15, 1990 Number 20 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

BACKGROUND AND METHODS. Laron-type dwarfism, which is characterized by the clinical appearance of isolated growth hormone deficiency with elevated serum levels of growth hormone and decreased serum levels of insulin-like growth factor I (IGF-I), has been described in approximately 50 patients. This condition is caused by a deficiency of the cellular receptor for growth hormone, and it is transmitted as an autosomal recessive trait, as indicated by an equal sex distribution and a high rate of consanguinity in affected families. We studied 20 patients (19 females and 1 male, 2 to 49 years of age), from an inbred Spanish population in southern Ecuador, who had the clinical features of Laron-type dwarfism. RESULTS. Seventeen patients were members of two large pedigrees. Among the 13 affected sibships, there were 19 affected and 24 unaffected female siblings and 1 affected and 21 unaffected male siblings. The patients' heights ranged from 10.0 to 6.7 SD below the normal mean height for age in the United States. In addition to the previously described features, 15 patients had limited elbow extensibility, all had blue scleras, affected adults had relatively short extremities, and all four affected women over 30 years of age had hip degeneration. Basal serum concentrations of growth hormone were elevated in all affected children (30 to 160 micrograms per liter) and normal to moderately elevated in the adults. The serum level of growth hormone-binding protein ranged from 1 to 30 percent of normal; IGF-I concentrations were low--less than or equal to 7 micrograms per liter in the children and less than or equal to 66 micrograms per liter in the adults (normal for Ecuadorean women, 98 to 238). Serum levels of IGF-II and growth hormone-dependent IGF-binding protein-3 were also low. CONCLUSIONS. We describe an inbred population with a high incidence of growth hormone-receptor deficiency resulting in a clinical picture resembling Laron-type dwarfism but differing principally in showing a marked predominance of affected females. This population, of Mediterranean origin, may be genetically related to other reported populations with Laron-type dwarfism, but with the genetic defect linked to a trait resulting in the early fetal death of most affected males.

Source Information

University of Florida, Gainesville.

This article has been cited by other articles:

• Sachdev, D., Yee, D. (2008). Disrupting Insulin-Like Growth Factor Signaling as a Potential Cancer Therapy. aacredbook 2008: 39-58 [Abstract] [Full Text]  
• Fang, P., Girgis, R., Little, B. M., Pratt, K. L., Guevara-Aguirre, J., Hwa, V., Rosenfeld, R. G. (2008). Growth Hormone (GH) Insensitivity and Insulin-Like Growth Factor-I Deficiency in Inuit Subjects and an Ecuadorian Cohort: Functional Studies of Two Codon 180 GH Receptor Gene Mutations. J. Clin. Endocrinol. Metab. 93: 1030-1037 [Abstract] [Full Text]  
• David, A., Camacho-Hubner, C., Bhangoo, A., Rose, S. J., Miraki-Moud, F., Akker, S. A., Butler, G. E., Ten, S., Clayton, P. E., Clark, A. J. L., Savage, M. O., Metherell, L. A. (2007). An Intronic Growth Hormone Receptor Mutation Causing Activation of a Pseudoexon Is Associated with a Broad Spectrum of Growth Hormone Insensitivity Phenotypes. J. Clin. Endocrinol. Metab. 92: 655-659 [Abstract] [Full Text]  
• Sachdev, D., Yee, D. (2007). Disrupting insulin-like growth factor signaling as a potential cancer therapy. Molecular Cancer Therapeutics 6: 1-12 [Abstract] [Full Text]  
• Camacho-Hubner, C., Rose, S., Preece, M. A., Sleevi, M., Storr, H. L., Miraki-Moud, F., Minuto, F., Frystyk, J., Rogol, A., Allan, G., Sommer, A., Savage, M. O. (2006). Pharmacokinetic Studies of Recombinant Human Insulin-Like Growth Factor I (rhIGF-I)/rhIGF-Binding Protein-3 Complex Administered to Patients with Growth Hormone Insensitivity Syndrome. J. Clin. Endocrinol. Metab. 91: 1246-1253 [Abstract] [Full Text]  
• Moore, C., Shalet, S., Manickam, K., Willard, T., Maheshwari, H., Baumann, G. (2005). Voice Abnormality in Adults with Congenital and Adult-Acquired Growth Hormone Deficiency. J. Clin. Endocrinol. Metab. 90: 4128-4132 [Abstract] [Full Text]  
• Coutant, R., de Casson, F. B., Rouleau, S., Douay, O., Mathieu, E., Gatelais, F., Bouhours-Nouet, N., Voinot, C., Audran, M., Limal, J. M. (2004). Divergent Effect of Endogenous and Exogenous Sex Steroids on the Insulin-Like Growth Factor I Response to Growth Hormone in Short Normal Adolescents. J. Clin. Endocrinol. Metab. 89: 6185-6192 [Abstract] [Full Text]  
• Maheshwari, H. G., Bouillon, R., Nijs, J., Oganov, V. S., Bakulin, A. V., Baumann, G. (2003). The Impact of Congenital, Severe, Untreated Growth Hormone (GH) Deficiency on Bone Size and Density in Young Adults: Insights from Genetic GH-Releasing Hormone Receptor Deficiency. J. Clin. Endocrinol. Metab. 88: 2614-2618 [Abstract] [Full Text]  
• Marzullo, P., Buckway, C., Pratt, K. L., Colao, A., Guevara-Aguirre, J., Rosenfeld, R. G. (2002). Leptin Concentrations in GH Deficiency: The Effect of GH Insensitivity. J. Clin. Endocrinol. Metab. 87: 540-545 [Abstract] [Full Text]  
• Amit, T., Youdim, M. B. H., Hochberg, Z.'e. (2000). Does Serum Growth Hormone (GH) Binding Protein Reflect Human GH Receptor Function?. J. Clin. Endocrinol. Metab. 85: 927-932 [Abstract] [Full Text]  
• (1999). The Essential Role of IGF-I: Lessons from the Long-Term Study and Treatment of Children and Adults with Laron Syndrome. J. Clin. Endocrinol. Metab. 84: 4397-4404 [Abstract] [Full Text]  
• (1999). Growth Hormone Receptor Deficiency in Ecuador. J. Clin. Endocrinol. Metab. 84: 4436-4443 [Full Text]  
• BJARNASON, R., SAVAGE, M. O (1999). Growth hormone insensitivity: a widening diagnosis. Arch. Dis. Child. 81: 378-379 [Full Text]  
• Sanchez, J. E., Perera, E., Baumbach, L., Cleveland, W. W. (1998). Growth Hormone Receptor Mutations in Children with Idiopathic Short Stature. J. Clin. Endocrinol. Metab. 83: 4079-4083 [Abstract] [Full Text]  
• Kranzler, J. H., Rosenbloom, A. L., Martinez, V., Guevara-Aguirre, J. (1998). Normal Intelligence with Severe Insulin-Like Growth Factor I Deficiency due to Growth Hormone Receptor Deficiency: A Controlled Study in a Genetically Homogeneous Population. J. Clin. Endocrinol. Metab. 83: 1953-1958 [Abstract] [Full Text]  
• Zhou, Y., Xu, B. C., Maheshwari, H. G., He, L., Reed, M., Lozykowski, M., Okada, S., Cataldo, L., Coschigamo, K., Wagner, T. E., Baumann, G., Kopchick, J. J. (1997). A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse). Proc. Natl. Acad. Sci. USA 94: 13215-13220 [Abstract] [Full Text]  
• Woods, K. A., Dastot, F., Preece, M. A., Clark, A. J. L., Postel-Vinay, M.-C., Chatelain, P. G., Ranke, M. B., Rosenfeld, R. G., Amselem, S., Savage, M. O. (1997). Phenotype: Genotype Relationships in Growth Hormone Insensitivity Syndrome. J. Clin. Endocrinol. Metab. 82: 3529-3535 [Abstract] [Full Text]  
• Baumbach, L., Schiavi, A., Bartlett, R., Perera, E., Day, J., Brown, M. R., Stein, S., Eidson, M., Parks, J. S., Cleveland, W. (1997). Clinical, Biochemical, and Molecular Investigations of a Genetic Isolate of Growth Hormone Insensitivity (Laron's Syndrome). J. Clin. Endocrinol. Metab. 82: 444-451 [Abstract] [Full Text]